Austedo (Deutetrabenazine) Patent Expiration, LOE Window & CMS Spending
Austedo (Deutetrabenazine) by Teva Pharmaceuticals: FDA Orange Book core substance LOE 2034-03-18 (last listed 2038-09-15), 0 AB generics, $1.30B 2024 CMS Part D & Medicaid spend, and 6 CA HCAI SB 17 wholesale price filings.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Teva Pharmaceuticals |
| FDA Application & Pathway | N208082 (NDA) |
| Exclusivity / Cliff Horizon | Long-Dated Protection (2036+) |
| Core Active-Ingredient LOE Date | 2034-03-18 |
| Last Listed Patent or Exclusivity Date | 2038-09-15 |
| Orange Book Patents (*PED Extensions) | 28 patents (14 *PED) |
| Active AB-Rated Generic Competitors | 0 |
| 2024 CMS Total Public Spend | $1.30B |
| 2024 Medicare Part D Spend | $1.07B |
| 2024 Medicaid Spend | $236.9M |
| Reported Wholesale Price Change (CA SB 17) | 6 WAC filings (max 22.0% 2-yr change) |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for Teva Pharmaceuticals across sibling Meru public-data platforms.